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Abstract
Peripheral T cell lymphoma (PTCL) is a rare and heterogeneous group of non-Hodgkin lymphomas with a very poor
prognosis. The standard first-line treatments have resulted in unsatisfactory patient outcomes. With the exception of
low-risk anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL), the majority of patients
relapse rapidly; the current 5-year overall survival rates are only 10–30 %. Novel targeted therapies and combination
chemotherapies are required for the treatment of patients with PTCL. In recent years, some retrospective and
prospective studies have been performed concerning PTCL. Consequently, a number of novel agents and their
relevant combination therapies have been identified, including histone deacetylase inhibitors, immunoconjugates,
antifolates, monoclonal antibodies, immunomodulatory agents, nucleoside analogs, proteasome inhibitors, kinase
inhibitors, bendamustine, L-asparaginase, and other targeted agents. It is hoped that these innovative approaches
will finally improve outcomes in patients with PTCL. This review summarizes the currently available approaches for
the treatment of PTCL with an emphasis on potential new agents, including the role of stem cell transplantation.
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Background
Peripheral T cell lymphoma (PTCL) is a rare and hetero-
geneous group of clinically aggressive diseases associated
with poor prognosis, which represents 10–15 % of non-
Hodgkin lymphomas. Twenty-three subtypes of PTCL
have been identified. They have been classified into four
groups using the World Health Organization (WHO)
classification system 2008, based on their clinical features
as follows: nodal, extranodal, cutaneous, and leukemic [1].
The International PTCL project that collected 1314 cases
of T/NK-cell lymphomas from 22 institutions worldwide
revealed that the most common subtypes worldwide are
the nodal T cell lymphomas [2]. In the nodal T cell lymph-
omas, the major subtypes are PTCL, not otherwise speci-
fied (PTCL-NOS), angioimmunoblastic T cell lymphoma
(AITL), anaplastic lymphoma kinase (ALK)-positive ana-
plastic large cell lymphoma (ALCL) and ALK-negative
ALCL. Among them, PTCL-NOS has been reported as
the major subtype worldwide and typically represents a
variant that does not meet the criteria for other subtypes.
The treatment approach of PTCL has traditionally been
similar to diffuse large B cell lymphoma (DLBCL); how-
ever, outcomes are poor when PTCL is treated according
to strategies established for aggressive B cell lymphomas
[3]. So far, the standard first-line therapy still consists of
cyclophosphamide, doxorubicin, vincristine, and prednis-
one (CHOP) or a CHOP-like regimen. Therapeutic re-
sponses to this approach have been neither adequate nor
durable [4, 5]. Because of poor outcome, there is an urgent
need to optimize induction therapy by incorporating novel
agents that target the different pathways. Novel thera-
peutic options that have been evaluated include histone
deacetylase (HDAC) inhibitors (HDACi), pralatrexate, and
monoclonal antibodies [6]. This review summarizes the
currently available approaches to treat PTCL, including
the role of stem cell transplantation (SCT).
Conventional therapy
Normally, CHOP is still the preferred choice of frontline
treatment for PTCL, although it has been disappointing
with the exception of low-risk ALK-positive ALCL. A sys-
tematic review evaluated CHOP or CHOP-like regimens
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in 2815 patients with PTCL, with a 5-year overall survival
(OS) of 38.5 % [4]. The German high-grade non-
Hodgkin’s Lymphoma study group (DSHNHL) analyzed
343 patients with 289 having tumors that belonged to one
of the four major subtypes of PTCL. Treatment consisted
of six to eight courses of CHOP or etoposide plus
(CHOEP). It was noted that the ALK-positive ALCL pa-
tients did particularly well with CHOEP, with a significant
improvement in both event-free survival and OS. Older
patients (age, > 60 years) did worse with the addition of
etoposide [5]. Because patients with ALK-positive ALCL
responded impressively to CHOP or CHOEP, the National
Comprehensive Cancer Network (NCCN) guidelines rec-
ommend the CHOP-21 or CHOEP-21 regimens as the
first-line therapy in ALK-positive ALCL. Because of less
favorable results, NCCN still recommends clinical trials
for first-line therapy in all other subtypes [7]. Several trials
have investigated whether the efficacy of CHOP could be
increased by the addition of novel agents as first-line
therapy; this is discussed below.
Novel agents and relevant combination therapies
To improve the outcome of patients with PTCL, the intro-
duction of novel agents is necessary. Recent research has
led to the development of numerous agents, including
HDACi, immunoconjugates, antifolates, monoclonal anti-
bodies, immunomodulatory agents, nucleoside analogs,
proteasome inhibitors, kinase inhibitors, bendamustine, L-
asparaginase, and other targeted agents. Some of these
novel agents can also be combined with other therapies to
enhance their efficacy.
Histone deacetylase inhibitors
There are approximately 18 different HDACs, which are
overexpressed in several tumor types. HDAC1 expression
is significantly higher in PTCL, suggesting a probable
mechanism of tumor suppression and sensitivity to
HDACi in T cell lymphoma (TCL) [8]. HDACi induces
histone acetylation, leading to increased expression of
tumor suppressor genes, consequently resulting in cell-
cycle arrest and cell differentiation. Two drugs have been
approved by the US Food and Drug Administration (FDA)
for PTCL: romidepsin and belinostat.
Romidepsin Romidepsin is a potent HDACi with a good
efficacy and safety profile in relapsed/refractory (R/R)
PTCL. It was approved by the FDA in 2011 for the treat-
ment of PTCL in patients who had received ≥ 1 prior ther-
apies. A previous phase II clinical trial (NCT00007345)
evaluated patients with refractory PTCL who had been
treated with romidepsin (14 mg/m2 administered as a 4-h
infusion on days 1, 8, and 15 of a 28-day cycle). There
were 45 patients included in this investigation who had a
median of three prior treatments. The overall response
rate (ORR) was 38 %, and eight patients experienced
complete remission (CR) after therapy. The median dur-
ation of response (DoR) was 8.9 (range 2–74) months.
The most common (≥ 40 %) adverse effects (AEs) included
nausea (51 %), thrombocytopenia (47 %), leukopenia
(47 %), granulocytopenia (45 %), fatigue (40 %), and
anemia (40 %) [9]. In a subsequent pivotal phase II trial,
130 patients with histologically confirmed R/R PTCL were
treated with romidepsin at the same dose for six cycles;
patients with at least stable disease (SD) were allowed
to continue until disease progression (NCT00426764)
[10–13]. Fifty patients (38 %) were treated for ≥ 4 cycles,
and 36 patients (28 %) received > 6 cycles. Most patients
had PTCL-NOS (n = 69), AITL (n = 27), or ALK-negative
ALCL (n = 21). The ORR was relatively high (25 %) con-
sidering that these patients had failed ≥ 1 prior therapies;
19 patients (15 %) had CR/unconfirmed CR (CRu), ten of
whom had a long-term (≥ 12 months) response. The
median DoR was 28 months. In patients who achieved
CR/CRu, median progression-free survival (PFS) was
29 months and OS was not reached. The most common
grade ≥ 3 AEs were thrombocytopenia (24 %), neutropenia
(20 %), and infections (19 %). This study also demon-
strated that prolonged romidepsin provides clinical bene-
fits for R/R patients who had achieved at least stable
disease. Romidepsin has been recommended by the
NCCN as a second-line and subsequent therapy in pa-
tients, regardless of intention to proceed to high-dose
therapy or SCT [7].
Because romidepsin alone has limited efficacy, trials
examining the combination of romidepsin with traditional
chemotherapy or newer agents are ongoing. In a single-
arm, phase Ib/II study (EudraCT2010-020962-91 and
NCT01280526), carried out at nine Lymphoma Study As-
sociation centers in France, 37 patients with previously
untreated PTCL received eight 3-week cycles of CHOP
with varying doses of romidepsin (8, 10, or 12 mg/m2 on
days 1 and 8). Based on this study, the recommended dose
of romidepsin for the phase II study was 12 mg/m2.
Among 35 evaluable patients in this study, the ORR
was 69 %, including 51 % with a CR. At the median
follow-up of 30 months, the estimated PFS and OS
were 41 and 71 %, respectively. Three patients had
early cardiac events, including two myocardial infarc-
tions and one acute cardiac failure. No deaths were
attributable to toxicity. Twenty-five patients had at least
one serious AE; the most common AEs were febrile neu-
tropenia, thrombocytopenia, lung infection, and vomiting
[14]. An ongoing phase III study, combining romidepsin
with CHOP (RoCHOP), will compare the outcome with
CHOP alone, to evaluate patient response rates and sur-
vival (NCT01796002). Romidepsin is also currently being
investigated in patients with PTCL in various combina-
tions, including with ICE (NCT01590732), lenalidomide
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(NCT01742793, NCT02232516), gemcitabine (NCT0182
2886), pralatrexate (NCT01947140), oral 5-azacitidine
(NCT01998035), or CHOEP (NCT02223208).
Belinostat Belinostat is a pan-HDAC inhibitor with anti-
tumor and anti-angiogenic properties. Belinostat has dem-
onstrated clinical benefit for patients with R/R PTCL in
the BELIEF trial. In this trial, there were 129 patients with
R/R PTCL who received belinostat (1000 mg/m2 adminis-
tered on days 1–5 of every 3-week cycle) for a median of
two cycles (range 1–33). The majority of patients received
CHOP/CHOP-like regimens prior to enrollment (96 %),
and the median number of systemic therapies was two. A
smaller proportion (23 %) of patients had previously
undergone SCT prior to enrollment. Among the 120 eva-
luable patients, 26 % of the remaining patients demon-
strated an ORR, with 11 % having a CR and 15 % a partial
response (PR). SD was seen in 15 % while 40 % had pro-
gressive disease (PD). In terms of the three most common
subtypes, ORR was seen in 23 % of patients with PTCL-
NOS, 46 % in AITL, and 15 % in ALK-negative ALCL.
The median PFS was 1.6 months, and the median OS was
7.9 months. In addition, 63.3 % of patients exhibited de-
creased tumor volume, and belinostat treatment enabled
12 patients to undergo SCT. These responses were ob-
served across PTCL subtypes and were durable, with a
median DoR of 13.6 months and an ongoing response
> 36 months in one patient. The most common grade
3/4 AEs were thrombocytopenia (13 %), neutropenia
(13 %), anemia (10 %), dyspnea (6 %), pneumonia
(6 %), and fatigue (5 %). Patients mainly discontinued
treatment as a result of PD (64 %); 7 % of patients dis-
continued treatment as a result of AEs [15, 16]. These
findings demonstrated the antitumor activity of beli-
nostat, resulting in its FDA approval in 2014 for pa-
tients with R/R PTCL; findings also suggested that the
combination of belinostat with other therapeutic agents
may improve clinical outcomes in PTCL. In another phase
II study (NCT00274651), Francine et al. evaluated the effi-
cacy and safety of belinostat (1000 mg/m2 administered
on days 1–5 of every 3-week cycle) in patients with either
PTCL or cutaneous T cell lymphoma (CTCL) [17]. There
were 24 patients with PTCL included in this analysis; all
had received a median of three prior systemic therapies
(range 1–9) and 40 % had stage IV disease. The ORRs
were 25 %, including a CR of 8 %. The median DoR was
109 days. In the PTCL cohort, grade 3/4 AEs reported as
being related to belinostat included five grade 3 AEs (ileus
paralytic, pneumonitis, rash maculo-papular, rash macular,
and cellulitis) and one grade 4 AE (thrombocytopenia).
Belinostat had no clear clinically relevant effect on electro-
cardiograms in this trial except for a minimal change in
the QTc duration in the 5–10-ms range, which is of
minimal clinical importance [17].
Chidamide Chidamide, a new oral isotype-selective
HDACi, approved in China for the treatment of R/R
PTCL in December 2014, is the first listed benzamide
class of HDACi in the world [18]. In a pivotal phase II
study (ChiCTR-TNC-10000811), 83 patients with R/R
PTCL were treated with chidamide at a dose of 30 mg or-
ally twice per week, and 79 patients was eligible. The ORR
was 28 % (22 of 79) including 14 % (11 of 79) with a CR/
CRu. The median DoR was 9.9 (range 1.1–40.8) months.
The median PFS and OS were 2.1 and 21.4 months,
respectively. AITL patients tended to have a higher ORR
(50 %) and CR/CRu rate (40 %), as well as more durable
responses. Most AEs were grade 1 or 2, and AEs of
grade ≥ 3 that occurred in ≥ 10 % patients were
thrombocytopenia (22 %), leucopenia (13 %), and neu-
tropenia (11 %), respectively. Chidamide has exhibited
significant single-agent activity and manageable tox-
icity in R/R PTCL in China. As a result of this study,
the CFDA has approved chidamide for the treatment
of R/R PTCL [19].
Immunoconjugates
Fusion proteins have been engineered to achieve the fol-
lowing: act as decoy receptors; increase the deliverability
of an active substance into the cells; add stability and
recruit immune effector cells; and fulfill other functions.
Brentuximab vedotin (BV) is an immunoconjugate that
combines an antitubulin agent with a CD30-specific
chimeric monoclonal antibody. A phase II study of BV
(1.8 mg/kg administered intravenously over 30 min every
3 weeks) in 58 ALCL patients reported an ORR of 86 %,
including 57 % with CRs, and a median DoR of
12.6 months. The median OS was not reached at the time
of the analysis; the estimated 12-month survival rate
was 70 %. The median PFS among all patients was
13.3 months. The most common (≥ 30 %) AEs were per-
ipheral sensory neuropathy (41 %), nausea (40 %), fatigue
(38 %), and pyrexia (34 %). The AEs led to treatment dis-
continuation in 24 % of patients. Based on the results of
this study, the US FDA and European Medicines Agency
(EMA), in 2011 and 2012, respectively, approved the use
of BV for patients with systemic ALCL after failure of ≥ 1
multi-agent chemotherapy regimen (NCT00866047) [20].
Another phase II trial of BV administered as the same
dose in 22 PTCL-NOS and 13 AITL patients reported an
ORR of 41 % with a median PFS of 2.6 months
(NCT01421667). No correlation between CD30 expres-
sion per central review and response was observed. Safety
data included grade ≥ 3 events involving neutropenia
(14 %), peripheral sensory neuropathy (9 %), and hyperka-
lemia (9 %) [21]. A phase I open-label study evaluated the
efficacy and safety of BV at a dose of 1.8 mg/kg every
3 weeks, administered sequentially with CHOP or in
combination with CHP (CHOP without vincristine) as
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frontline treatment in patients with CD30-positive PTCL
(NCT01309789). Thirty-nine patients were enrolled in the
study (13 and 26 patients in the sequential- and
combination-treatment groups, respectively). After sequ-
ential treatment, 11 (85 %) patients achieved an objective
response (62 % CR; 77 % estimated 1-year PFS), with
grade 3/4 AEs in 62 %. At the end of combination treat-
ment, patients (n = 26) achieved an objective response
(88 % CR; 71 % estimated 1-year PFS). Grade 3/4 AEs
(≥ 10 %) in the combination-treatment group were fe-
brile neutropenia (31 %), neutropenia (23 %), anemia
(15 %), and pulmonary embolism (12 %). This study
demonstrated a manageable safety profile and exhibited
substantial antitumor activity in newly diagnosed pa-
tients with CD30-positive PTCL [22]. A randomized
phase III trial is underway, comparing a combination of
BV and CHP with CHOP alone (NCT01777152).
Antifolates
Pralatrexate, an antimetabolite drug, selectively enters
cells through reduced folate carrier type 1 (RFC-1), which
is a protein that transports reduced natural folates into
highly proliferative cells. A large prospective study (PRO-
PEL) enrolled 115 patients, of whom 109 were evaluable.
Patients received pralatrexate intravenously at a dose of
30 mg/m2/week for 6 weeks in 7-week cycles until disease
progression or the development of unacceptable toxicity.
An ORR of 29 % was reported, with 12 (11 %) patients
achieving a CR/CRu, 20 (18 %) a PR, and 21 (19 %) SD.
The median DoR was 10.1 months, and the median PFS
and OS were 3.5 and 14.5 months, respectively. The most
common AEs were mucositis (71 %), and grade 3/4 AEs
were thrombocytopenia (33 %), mucositis (22 %), neutro-
penia (22 %), and anemia (18 %). No cumulative myelo-
suppression was observed with continued pralatrexate
treatment [23]. Based on this study, the US FDA Office of
Oncology Drug Products granted accelerated approval
to pralatrexate injection for the treatment of patients
with R/R PTCL in September 2009. However, in January
2012, the Committee for Medicinal Products for Human
Use (CHMP) refused marketing authorization for the
FDA-approved pralatrexate for PTCL treatment and con-
firmed their refusal on 19 April 2012. The CHMP was
concerned that this study was designed in a way that did
not allow the Committee to assess the benefits of the
drug; this was particularly true because pralatrexate was
not compared with any other treatment or placebo in an-
other group of patients. Moreover, there was no clear im-
provement seen in the condition of the patients because
the study investigated patient response to treatment but
did not further allow the Committee to assess its effect
on OS or PFS. The CHMP was of the opinion that
there was insufficient evidence to establish the benefits
of pralatrexate in the treatment of PTCL. Therefore,
the CHMP was of the opinion that the benefits of pra-
latrexate did not outweigh its risks and recommended
that it be refused marketing authorization. Currently,
there are only three ongoing clinical trials involving prala-
trexate, combined with CHOP (NCT02594267), romidep-
sin (NCT01947140), or oral leucovorin (NCT02106650).
Monoclonal antibodies
Alemtuzumab Alemtuzumab is an anti-CD52 monoclo-
nal antibody that is known to suppress immunity, includ-
ing the depletion of CD4 and CD8 T cells as well as B
cells. It has undergone early stage evaluation, but severe
immunocompromise and neutropenia have limited its use.
Alemtuzumab combined with other therapies has also
been investigated. In a prospective phase II trial, 29
(70.7 %) of the 41 patients received CHO(E)P followed by
alemtuzumab consolidation (133 mg in total). The CR rate
was 58.5 %, and EFS and OS at 3 years in the whole
intent-to-treat population were 32.3 and 62.5 %, respect-
ively; EFS and OS at 3 years were 42.4 and 75.1 % in the
patients who had received alemtuzumab. The main grade
3/4 toxicities were infections and neutropenia with one
potential treatment-related death (NCT01806337) [24]. A
phase II study of patients with newly diagnosed (n = 27) or
R/R (n = 11) PTCL received a combination of alemtuzu-
mab, fludarabine, cyclophosphamide, and doxorubicin.
The ORR was 61 %, with a CR of 39 %. In newly diag-
nosed patients, the ORR was 63 %, the median OS was
25.9 months, and the PFS was 11.8 months. In R/R pa-
tients, the median OS was 6.1 months. The most frequent
grade 3/4 toxicities were leukopenia (95 % of patients) and
thrombocytopenia (58 %). Cytomegalovirus (CMV) re-
activation occurred in 12 patients, but only two had
CMV disease. Treatment-related deaths occurred in six
newly diagnosed patients and one with R/R disease
[25]. Alemtuzumab-based therapy was active in PTCL
but was also associated with significant toxicity.
Mogamulizumab Mogamulizumab is a monoclonal anti-
body targeting CC chemokine receptor 4 (CCR4). Regula-
tory T cells (Tregs) that overexpress CCR4 in aggressive
PTCL impair host antitumor immunity and provide an
environment for the tumor to grow. Mogamulizumab de-
pletes CCR4-positive Tregs, potentially evoking antitumor
activity. A phase II study of weekly administered mogamu-
lizumab infusions at a dose of 1.0 mg/kg in 27 patients
with relapsed, aggressive CCR4-positive TCL showed
an ORR of 50 %, including 31 % with a CR. The
median PFS was 5.2 months, and the median OS was
13.7 months. The most common (≥ 15 %) grade 3/4
AEs were lymphopenia (74 %), leukocytopenia (30 %),
thrombocytopenia (19 %), neutropenia (19 %), and
rash (19 %) (NCT00920790) [26]. Another phase II
study of mogamulizumab at the same dose in 38
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patients, of whom 37 were evaluable with relapsed
CCR4-positive PTCL or CTCL, reported an ORR of
35 %, including 14 % with a CR; the median PFS was
3 months. The most common (≥ 15 %) grade 3/4 AEs
were lymphocytopenia (73 %) and neutropenia (19 %)
(NCT01192984) [27].
Zanolimumab Zanolimumab is a biologically active
monoclonal antibody that targets the CD4 antigen present
on subsets of PTCL. This antibody was studied in a phase
II study, including 21 R/R patients with CD4-positive
PTCL (NCT00877656). Weekly zanolimumab infusions at
a dose of 980 mg for 12 weeks achieved an ORR of 24 %,
and 10 % of patients had a CR. Drug-related grade 3 AEs
occurred in lymphocytopenia (10 %), infusion-related
AEs (10 %), and arthralgia (5 %), which were well toler-
ated [28].
Immunomodulatory agents
The immunomodulatory drug lenalidomide acts by inhib-
ition of vascular endothelial growth factor (VEGF), activa-
tion of natural killer cells and T lymphocytes, and
modulation of various cytokines such as tumor necrosis
factor-α, interleukin-12, and interferon-γ. They also exert
a direct effect on cell-cycle arrest and apoptosis, thus be-
ing able to target both neoplastic cells and the tumor
microenvironment. Lenalidomide (25 mg orally on days
1–21 of each 28-day cycle) has shown efficacy in patients
with R/R PTCL [29–31]. A phase II study involving 23
evaluable patients showed an ORR of 30 % (all PRs). The
median PFS and OS were 3.2 and 7.9 months, respectively.
AEs were consistent with the known safety profile of
lenalidomide. The most common grade 3/4 AEs were
thrombocytopenia (42 %), neutropenia (21 %), dyspnea
(17 %), febrile neutropenia (17 %), pain (17 %), and pneu-
monitis (17 %). Study discontinuation was mainly for PD
(46 %); four patients (17 %) discontinued treatment as a
result of AEs [29]. The multicenter phase II EXPECT trial
included 54 patients with R/R PTCL, mostly with AITL
(n = 26; 48 %) and PTCL-NOS (n = 20; 37 %). The ORR
was 22 % (11 % CR/CRu). The median PFS and DoR were
2.5 and 3.6 months, respectively. The most common grade
3/4 AEs (≥ 15 %) included thrombocytopenia (20 %),
gastrointestinal disorders (17 %), neutropenia (15 %), and
infections (15 %) [30]. Recently, a phase II trial in 40
patients (one ineligible) with R/R and untreated PTCL
reported an ORR of 26 % (8 % CR). Three patients had SD
for five cycles (NCT00322985). The median OS was
12 months, the median PFS was 4 months, and the me-
dian DoR was 13 months, including five patients with
treatment responses that lasted > 1 year. Among the pa-
tients who had R/R PTCL (29 patients), the ORR was
24 %, the median OS was 12 months, the median PFS was
4 months, and the median DoR was 5 months. The most
common grade 4 AEs were pain, not otherwise specified
(21 %), neutropenia (13 %), muscle weakness (10 %), and
dyspnea (10 %); dehydration (10 %) was the most com-
monly reported grade 3 AE [31]. Because of the limited
efficacy of lenalidomide as a single agent in PTCL, the
combination therapies of lenalidomide and romidepsin
are currently under investigation, including in the
NCT02232516 trial involving untreated patients and the
NCT01742793 trial involving R/R patients.
Nucleoside analogs
Nucleoside analogs are chemotherapeutic agents that pri-
marily inhibit DNA replication and repair. These agents
are cytotoxic to both proliferating and non-proliferating
cells. The nucleoside analogs include gemcitabine, pentos-
tatin, cladribine, fludarabine, clofarabine, forodesine, and
nelarabine. Gemcitabine, cladribine, and fludarabine have
shown efficacy in PTCL, and gemcitabine is the most ef-
fective pyrimidine nucleoside analog in PTCL; it has been
included in the NCCN guidelines as second-line therapy
for patients with relapsed PTCL [7] and has been incorpo-
rated into several combination chemotherapy regimens.
Zinzani et al. reported on the efficacy and safety of 20 pre-
treated PTCL-NOS patients treated with gemcitabine
[32]. All patients had stage III–IV disease. Gemcitabine
was given on days 1, 8, and 15 involving a 28-day schedule
(1200 mg/m2/day) for a total of three to six cycles. Pa-
tients had a CR rate of 30 % and a PR rate of 25 %. Among
the CR patients, five were in continuous CR with a vari-
able disease-free survival (DFS) (15–60 months). Gemcita-
bine was generally well tolerated; there was no grade 3/4
hematological toxicity, and all of the responding patients
completed the treatment [32]. The first prospective CISL
trial investigated the efficacy and tolerability of a salvage
GDP regimen for 25 R/R PTCL patients. Treatment con-
sisted of gemcitabine at a dose of 1000 mg/m2 intraven-
ously on days 1 and 8, dexamethasone at a dose of 40 mg
orally on days 1–4, and cisplatin 70 mg/m2 intravenously
on day 1, every 21 days. The median number of GDP cy-
cles was four. The ORR was 72 %, including 12 patients
with a CR (48 %) and six with a PR (24 %). Four patients
proceeded to autologous SCT (ASCT), and three patients
finally achieved a CR. The median PFS was 9.3 months
with a median follow-up duration of 27.1 months. In a
total of 86 cycles of GDP, grade 3 or 4 neutropenia and
thrombocytopenia occurred in 16.3 and 12.8 % of the
cycles, respectively. Three patients (3.3 %) experienced
febrile neutropenia [33]. In these studies, gemcitabine was
well tolerated and effective.
Proteasome inhibitors
Bortezomib, a proteasome inhibitor, has been well toler-
ated and active as a single or combinational agent in
PTCL patients. In a phase II study in 15 relapsed CTCL
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or PTCL patients, bortezomib (1.3 mg/m2 intravenously
on days 1, 4, 8, and 11, every 21 days for a total of six
cycles) produced an ORR of 67 %, with two CRs and no
grade 4 toxicity [34]. A large multicenter phase II trial
involving 46 patients evaluated bortezomib plus CHOP
in a frontline setting. Although the ORR was 76 % and
the CR was 65 %, the 3-year OS and PFS were 47 and
35 %, respectively, as a result of frequent relapse after
remission. The outcome was similar to CHOP alone.
Grade 3/4 leucopenia was the most frequent toxicity,
whereas neurotoxicity was tolerable (NCT00374699)
[35]. Another phase I/II trial involved bortezomib
(1.6 mg/m2) given concurrently with gemcitabine
(800 mg/m2) on days 1 and 8 of a 21-day cycle. Of 32
patients, 16 each had R/R PTCL and DLBCL. Among
the first 18 patients, 67 % experienced grade 3/4 neutro-
penia and/or grade 3/4 thrombocytopenia resulting in
repeated treatment delays. Thus, the study was amended
to give bortezomib and gemcitabine on days 1 and 15 of
a 28-day cycle, which resulted in markedly improved tol-
erability. The ORR for PTCL was 36 % (CR, 27 %).
Among six PTCL patients treated using the modified
schedule, the intent-to-treat ORR was 50 % (CR, 30 %)
[36]. The NCCN has recommended bortezomib as a
second-line therapy for patients without intention to
proceed to transplantation [7].
Kinase inhibitors
Aurora A kinase (AAK) inhibitors AAK is a mitotic
kinase implicated in oncogenesis and has been found to
be upregulated in PTCL, most strongly in ALK-positive
ALCL, followed by ALK-negative ALCL and PTCL-NOS
[37]. A phase II trial evaluated its efficacy against a variety
of NHL. In this trial, patients received alisertib at a dose of
50 mg twice daily for 7 days in 21-day cycles, until
PD or unacceptable toxicities developed. The ORR in
48 enrolled patients was 27 and 50 % in eight PTCL pa-
tients. Common drug-related grade 3/4 AEs included
neutropenia (63 %), leukopenia (54 %), anemia (35 %),
thrombocytopenia (33 %), and stomatitis (15 %) [38]. An-
other phase II intergroup trial (SWOG 1108) enrolled 37
pretreated PTCL patients. Among the PTCL subtypes, the
ORR was 30 %; however, no responses were observed in
patients with transformed Mycosis fungoides. The me-
dian DoR was 3 months. The estimated median PFS
and OS were 3 and 8 months, respectively. Grade 3/4
AEs in ≥ 5 % of patients included neutropenia (32 %),
anemia (30 %), thrombocytopenia (24 %), febrile neutro-
penia (14 %), mucositis (11 %), and rash (5 %). Treatment
was most frequently discontinued because of disease pro-
gression. Based on these results, a randomized phase III
trial of alisertib versus the investigator’s choice is underway
for patients with relapsed PTCL (NCT01482962) [39].
Tyrosine kinase In patients with ALK-positive ALCL,
there are efforts to study the use of crizotinib, an oral
small-molecule tyrosine kinase inhibitor of ALK, which
has been FDA approved for the treatment of lung cancer
harboring a translocation in the ALK gene. In a small study
consisting of 11 patients with refractory ALK-positive
lymphoma, nine had ALCL histology. Patients received cri-
zotinib at a dose of 250 mg twice daily as monotherapy
until disease progression. There was an ORR in 91 % of
patients. The OS was 72.7 %, and the PFS was 63.7 % at
2 years; three patients had a CR for > 30 months under
continuous crizotinib administration. All toxicities were
grade 1/2, including ocular flashes, peripheral edema, and
neutropenia [40]. Crizotinib exerted potent antitumor ac-
tivity in advanced ALK-positive lymphoma patients; a clin-
ical trial evaluating crizotinib in patients with primary
ALK-positive systemic ALCL is ongoing (NCT02487316).
Bendamustine
Bendamustine is an alkylating agent with antimetabolite
properties that exhibits activity in several hematologic
malignancies and solid tumors. In the BENTLY trial, 60
patients with CTCL and PTCL (mainly AITL and PTCL-
NOS) were treated with bendamustine infused at a dose
of 120 mg/m2 on days 1 and 2 every 3 weeks, for six
cycles. Twenty patients (33 %) received fewer than three
cycles of bendamustine, mostly because of disease pro-
gression. The ORR was 50 %, including a CR in 17
patients (28 %) and a PR in 13 patients (22 %). The
median DoR was 3.5 months, with 30 % of responses last-
ing > 6 months. The median PFS and OS were 3.6 and
6.2 months, respectively. The most frequent (≥ 5 %) grade
3/4 AEs were neutropenia (30 %), thrombocytopenia
(24 %), and infections (20 %). Infections and hematological
AEs led to discontinuation in five patients (8 %) [41]. Be-
cause bendamustine showed an encouraging response rate
and acceptable toxicity, the NCCN has recommended it
as a second-line and subsequent therapy, regardless of
high-dose therapy and SCT [7].
L-asparaginase
L-asparaginase (L-ASP) is a naturally occurring enzyme
and exerts its antitumor activity by depleting circulat-
ing pools of L-asparagine, which is an essential amino
acid for protein synthesis. Few reports have shown that
L-ASP can be effective against PTCL as well as NK/T
cell lymphomas. Tsutomu et al. presented a relapse pa-
tient with Epstein-Barr virus (EBV)-positive cytotoxic
PTCL-NOS, who was successfully treated using only L-
ASP. L-ASP treatment was initiated at 6000 U/m2 on
days 1, 3, 5, 10, and 12 together with prednisolone at a
dose of 1 mg/kg. Although he developed grade 2 liver
dysfunction and grade 2 coagulopathy, the patient
achieved CR status [42]. A retrospective study analyzed
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102 patients with incipient PTCL who received L-ASP
(administered as 6000 U/m2, once a day, for 7 days)
with or without multi-drug chemotherapy regimens.
Patients who received L-ASP containing multi-drug
chemotherapy (L-ASP group) had higher ORRs than
those who received non L-ASP (83.3 vs. 61.7 %; P =
0.016), particularly those at stage III/IV (82.4 vs. 54 %;
P = 0.007) and with an international prognostic index
(IPI) score of ≥ 2 (82.1 vs. 50 %; P = 0.006). The median
OS of the L-ASP and non L-ASP groups was 10.5 and
13 months, respectively, and the median PFS was 10
and 11 months, respectively. The 3-year OS rate of the
L-ASP and non L-ASP groups was 48.9 and 65 %, re-
spectively, and the 3-year PFS rate was 40.8 and 61 %,
respectively. None of these values differed significantly.
Although the incidence of AEs was higher in the L-ASP
group, most of them were mild and controllable after sup-
portive treatment. There was no significant difference in
serious infections caused by grade 3/4 neutropenia be-
tween the two groups (P = 0.777). Other severe AEs in the
L-ASP group, such as hematencephalon and acute pan-
creatitis, were only seen in one case. L-ASP showed better
short-term efficacy in PTCL patients [43].
Other targeted agents
Some other novel agents in use or under investigation
seem to have more targeted action. The mTOR pathway is
constitutively activated in the TCL cells and is responsible
for TCL proliferation. A phase II study first demonstrated
that mTORC1 inhibitors (everolimus) have substantial an-
titumor activity in relapsed TCL patients (NCT00436618).
In the clinical trial, 16 patients with relapsed TCL were
enrolled and received oral everolimus at a dose of 10 mg
daily. The ORR was 44 % (7/16). The median PFS was
4.1 months, and the median OS was 10.2 months. The
Table 1 Clinical trial efficacy results of novel single-agent treatments




Outcomes ClinicalTrial.gov ID References
Tipifarnib Farnesyltransferase
inhibitor
II 12 PTCL 50 % ORR NCT00082888 [49]
Darinaparsin Organic arsenic
compound
II 7 PTCL 28.6 % ORR, 3.6 months















I 4 PTCL 1 PR NCT00893464 [53]
Sorafenib Multikinase
inhibitor
— 12 PTCL/CTCL 42 % ORR, 4 CR, 1 PR — [54]
Forodesine PNP inhibitor II 101 CTCL No CR, 11 % PR, 50 % SD,
median DoR was 191 days
NCT00501735 [55]
ORR overall response rate, CR complete response, PR partial response, SD stable disease, TTF time to treatment failure, OS overall survival, DoR duration of
response, PNP purine nucleoside phosphorylase
Table 2 Ongoing clinical trials of novel agents in patients with
PTCL





















Forodesine PNP inhibitor I/II NCT01776411
Ruxolitinib JAK inhibitor II NCT01431209










MK2006 AKT inhibitor II NCT01258998




Pembrolizumab PD-1 antibody II NCT02535247
PNP purine nucleoside phosphorylase, JAK Janus kinases, mTOR mammalian
target of rapamycin, PD-1 programmed death-1
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median DoR for the seven responders was 8.5 months.
Seven patients had a grade ≥3 hematological toxicity
and six had grade 3 nonhematological toxicity [44]. Re-
cent studies have shown that specific inhibition of IDH
mutants can reverse the abnormal methylations be-
cause of the mutation, and had efficacy in pre-clinical
and clinical studies [45]; AG-221 acted on IDH2 mutation
and is in a clinical trial (NCT02273739). A recent case
study reported on the efficacy of the hypomethylating agent
5-azacytidine in an AITL patient with a TET2 mutation
[46]. Other novel therapeutic agents, such as ruxolitinib,
that act on the JAK/STAT pathway are being investi-
gated in clinical trials (e.g., NCT01431209). Clinical
trial efficacy results regarding novel single-agent treat-
ments, as well as ongoing clinical trials of PTCL, are
summarized in Tables 1 and 2.
Stem cell transplantation
Relapses in patients with PTCL are common; therefore,
SCT as a consolidation and salvage strategy has been
chosen to enhance therapeutic results. The NCCN guide-
line has recommended ASCT as an option for consolida-
tion after first remission in patients with histologies other
than ALK-positive ALCL with low international prognos-
tic index scores [7, 47]. However, there have been no
randomized controlled trials to restrict patients who can
benefit from ASCT or achieve an objective response im-
mediately after induction chemotherapy, with the excep-
tion of low-risk ALK-positive ALCL. Moreover, the role of
ASCT in relapsed PTCL remains to be determined and
thus cannot be compared with allogeneic SCT (allo-SCT).
Some limited studies have evaluated the efficacy of ASCT
and allo-SCT in relapsed PTCL. The largest retrospective
study included 76 patients with TCL who had been treated
using ASCT or allo-SCT protocols at the MD Anderson
Cancer Center between 1990 and 2009. For ASCT for re-
lapsed disease, 41 patients were studied. The 4-year OS
and PFS rates were 50 and 38 %, respectively, for ASCT
patients. Patients with CR2/3 had a 4-year OS rate of 59 %
after ASCT, suggesting that remission status before trans-
plantation is required for good results. This study also
presented the role of allo-SCT in 35 PTCL patients in re-
lapsed disease. With a median follow-up of 45 months for
allo-SCT, the 4-year OS and PFS were 36 and 28 %, re-
spectively. The 4-year non-relapse mortality (NRM) rate
was significantly higher in allo-SCT than in ASCT pa-
tients (40 vs. 17 %; P < 0.001) [48]. Allo-SCT did not result
in a superior outcome relative to ASCT, and the inferior
OS survival seen with allo-SCT was in large part caused
by the increased NRM.
Conclusions
Although the treatment of PTCL has undergone signifi-
cant changes during the last few years, the response rate
and long-term effect for patients with PTCL remains un-
satisfactory. An increasing number of studies have identi-
fied signal pathway and gene abnormalities in PTCL, such
as the NF-κB and mTOR pathways, and the IDH and
TET2 mutations. There is no specific stratification of ther-
apy for all PTCLs. Genetic and proteomic techniques
probably contribute to the accurate treatment options. For
instance, ALK-positive PTCL patients treated with crizo-
tinib or brentuximab vedotin exhibit preferable responses.
Multiple pathways are involved in the pathogenesis of
some specific subtypes of PTCL, which make combined
therapy possible. Some studies involving the combination
of romidepsin with pralatrexate or lenalidomide are on-
going. We expect further research results in the future.
As well as novel targeted agents, the role and timing of
stem cell transplantation in the majority of PTCL patients
are still elusive. This problem is difficult to resolve because
of insufficient data from randomized controlled trials in-
volving rare and heterogeneous PTCL. Investigators are
faced with the challenge of selecting from the promising
strategies available for PTCL subtypes. New diagnostic
tools and molecular genetic markers could further subdiv-
ide PTCL patients and assist clinical investigators to select
the correct therapeutic options. Individualized treatment
would be a promising approach for PTCL in the future.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
ZYP and LH reviewed the literatures and wrote the manuscript. XW and LJY
revised the manuscript critically for important content. All authors read and
approved the final manuscript.
Acknowledgements
This work was supported by the National Natural Science Foundation of
China (30971296, 81170485, 81170488, 81370657, and 81470328), Key
Projects of the Health Department of Jiangsu Province (K201108), Jiangsu
Province’s Medical Elite Programme (RC2011169), the National Public Health
Grand Research Foundation (201202017), a project funded by the Priority
Academic Programme Development of Jiangsu Higher Education Institute
(JX10231801), Project of National Key Clinical Specialty, the National Science
and Technology Pillar Programme (2014BAI09B12), and a project funded by
Jiangsu Provincial Special Programme of Medical Science (BL2014086).
Author details
1Department of Hematology, The First Affiliated Hospital of Nanjing Medical
University, Jiangsu Province Hospital, Nanjing 210029, China. 2Department of
Hematology, Affiliated Hospital of Nantong University, Nantong 226000,
China. 3Collaborative Innovation Center For Cancer Personalized Medicine,
Nanjing Medical University, Nanjing 210029, China.
Received: 25 January 2016 Accepted: 6 April 2016
References
1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J,
Vardiman JW. WHO classification of tumours of haematopoietic and
lymphoid tissues. 4th ed. France: IARC Press; 2008.
2. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and
natural killer/T-cell lymphoma study: pathology findings and clinical
outcomes. J Clin Oncol. 2008;26(25):4124–30.
Zhang et al. Journal of Hematology & Oncology  (2016) 9:37 Page 8 of 10
3. Foss F. Hematology: relapsed and refractory PTCL—into the therapeutic
abyss. Nat Rev Clin Oncol. 2011;8(6):321–2.
4. Abouyabis AN, Shenoy PJ, Sinha R, Flowers CR, Lechowicz MJ. A systematic
review and meta-analysis of front-line anthracycline-based chemotherapy
regimens for peripheral T-cell lymphoma. ISRN Hematol. 2011;2011:623924.
5. Schmitz N, Trumper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, Peter N,
Loeffler M, Rosenwald A, Pfreundschuh M. Treatment and prognosis of
mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell
lymphoma treated in studies of the German High-Grade Non-Hodgkin
Lymphoma Study Group. Blood. 2010;116(18):3418–25.
6. Karlin L, Coiffier B. The changing landscape of peripheral T-cell lymphoma
in the era of novel therapies. Semin Hematol. 2014;51(1):25–34.
7. NCCN Clinical Practice Guidelines in Oncology. Non-Hodgkin’s lymphoma,
V.2.2015. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
Accessed 23 March 2015.
8. Marquard L, Poulsen CB, Gjerdrum LM, de Nully BP, Christensen IJ, Jensen
PB, Sehested M, Johansen P, Ralfkiaer E. Histone deacetylase 1, 2, 6 and
acetylated histone H4 in B- and T-cell lymphomas. Histopathology. 2009;
54(6):688–98.
9. Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, Jaffe ES, Ling
A, Turner M, Peer CJ, Figg WD, Steinberg SM, Smith S, Joske D, Lewis I,
Hutchins L, Craig M, Fojo AT, Wright JJ, Bates SE. Phase 2 trial of romidepsin
in patients with peripheral T-cell lymphoma. Blood. 2011;117(22):5827–34.
10. Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D,
Borchmann P, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan S,
Shustov A, Nichols J, Carroll S, Balser J, Balser B, Horwitz S. Results from a
pivotal, open-label, phase II study of romidepsin in relapsed or refractory
peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;
30(6):631–6.
11. Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D,
Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan Iyer S, Shustov
A, Nielsen T, Nichols J, Wolfson J, Balser B, Horwitz S. Romidepsin for the
treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study
update demonstrates durable responses. J Hematol Oncol. 2014;7:11.
12. Foss F, Coiffier B, Horwitz S, Pro B, Prince HM, Sokol L, Greenwood M, Lerner
A, Caballero D, Baran E, Kim E, Nichols J, Balser B, Wolfson J, Whittaker S.
Tolerability to romidepsin in patients with relapsed/refractory T-cell
lymphoma. Biomark Res. 2014;2:16.
13. Foss F, Horwitz S, Pro B, Prince HM, Sokol L, Balser B, Wolfson J, Coiffier B.
Romidepsin for the treatment of relapsed/refractory peripheral T cell
lymphoma: prolonged stable disease provides clinical benefits for patients
in the pivotal trial.
J Hematol Oncol. 2016;9(1):22.
14. Dupuis J, Morschhauser F, Ghesquieres H, Tilly H, Casasnovas O,
Thieblemont C, Ribrag V, Bossard C, Bras FL, Bachy E, Hivert B, Nicolas-
Virelizier E, Jardin F, Bastie JN, Amorim S, Lazarovici J, Martin A, Coiffier B.
Combination of romidepsin with cyclophosphamide, doxorubicin,
vincristine, and prednisone in previously untreated patients with peripheral
T-cell lymphoma: a non-randomised, phase 1b/2 study. Lancet Haematol.
2015;2(4):e160–5.
15. O’Connor OA, Masszi T, Savage KJ. Belinostat, a novel pan-histone
deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell
lymphoma (R/R PTCL): Results from the BELIEF trial. J Clin Oncol (ASCO
Meeting Abstact). 2013;31(15_Suppl):8507.
16. O’Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J, Hess
G, Jurczak W, Knoblauch P, Chawla S, Bhat G, Choi MR, Walewski J, Savage
K, Foss F, Allen LF, Shustov A. Belinostat in patients with relapsed or
refractory peripheral T-cell lymphoma: results of the Pivotal Phase II BELIEF
(CLN-19) Study. J Clin Oncol. 2015;33(23):2492–9.
17. Foss F, Advani R, Duvic M, Hymes KB, Intragumtornchai T, Lekhakula A,
Shpilberg O, Lerner A, Belt RJ, Jacobsen ED, Laurent G, Ben-Yehuda D,
Beylot-Barry M, Hillen U, Knoblauch P, Bhat G, Chawla S, Allen LF, Pohlman
B. A Phase II trial of Belinostat (PXD101) in patients with relapsed or
refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2015;
168(6):811–9.
18. Gu R, Liu T, Zhu X, Gan H, Wu Z, Li J, Zheng Y, Dou G, Meng Z.
Development and validation of a sensitive HPLC-MS/MS method for
determination of chidamide (epidaza), a new benzamide class of
selective histone deacetylase inhibitor, in human plasma and its clinical
application. J Chromatogr B Analyt Technol Biomed Life Sci. 2015;1000:
181–6.
19. Shi Y, Dong M, Hong X, Zhang W, Feng J, Zhu J, Yu L, Ke X, Huang H, Shen
Z, Fan Y, Li W, Zhao X, Qi J, Zhou D, Ning Z, Lu X. Results from a
multicenter, open-label, pivotal phase II study of chidamide in relapsed or
refractory peripheral T-cell lymphoma. Ann Oncol. 2015;26(8):1766–71.
20. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J,
Ramchandren R, Fanale M, Connors JM, Yang Y, Sievers EL, Kennedy DA,
Shustov A. Brentuximab vedotin (SGN-35) in patients with relapsed or
refractory systemic anaplastic large-cell lymphoma: results of a phase II
study. J Clin Oncol. 2012;30(18):2190–6.
21. Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O’Connor OA,
Siddiqi T, Kennedy DA, Oki Y. Objective responses in relapsed T-cell
lymphomas with single-agent brentuximab vedotin. Blood. 2014;123(20):
3095–100.
22. Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, Chen
RW, Davies A, Illidge T, Huebner D, Kennedy DA, Shustov AR. Brentuximab
vedotin in the front-line treatment of patients with CD30+ peripheral T-cell
lymphomas: results of a phase I study. J Clin Oncol. 2014;32(28):3137–43.
23. O’Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B,
Lechowicz MJ, Savage KJ, Shustov AR, Gisselbrecht C, Jacobsen E, Zinzani
PL, Furman R, Goy A, Haioun C, Crump M, Zain JM, Hsi E, Boyd A, Horwitz S.
Pralatrexate in patients with relapsed or refractory peripheral T-cell
lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29(9):
1182–9.
24. Binder C, Ziepert M, Pfreundschuh M, Duhrsen U, Eimermacher H, Aldaoud
A, Rosenwald A, Loeffler M, Schmitz N, Truemper L. CHO(E)P-14 followed by
alemtuzumab consolidation in untreated peripheral T cell lymphomas: final
analysis of a prospective phase II trial. Ann Hematol. 2013;92(11):1521–8.
25. Weidmann E, Hess G, Chow KU, Krause SW, Subklewe M, Kruse J, Weisel KC,
Soekler M, Kim SZ, Napieralski S, Rech J, Dreyling M, Jager E, Mitrou PS. A
phase II study of alemtuzumab, fludarabine, cyclophosphamide, and
doxorubicin (Campath-FCD) in peripheral T-cell lymphomas. Leuk
Lymphoma. 2010;51(3):447–55.
26. Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, Saburi Y,
Miyamoto T, Takemoto S, Suzushima H, Tsukasaki K, Nosaka K, Fujiwara H,
Ishitsuka K, Inagaki H, Ogura M, Akinaga S, Tomonaga M, Tobinai K, Ueda R.
Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult
T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;
30(8):837–42.
27. Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, Fujimoto K,
Yamamoto K, Miyamoto T, Uike N, Tanimoto M, Tsukasaki K, Ishizawa K,
Suzumiya J, Inagaki H, Tamura K, Akinaga S, Tomonaga M, Ueda R.
Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated
anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral
T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014;32(11):
1157–63.
28. d’Amore F, Radford J, Relander T, Jerkeman M, Tilly H, Osterborg A,
Morschhauser F, Gramatzki M, Dreyling M, Bang B, Hagberg H. Phase II trial
of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous
peripheral T cell lymphoma. Br J Haematol. 2010;150(5):565–73.
29. Dueck G, Chua N, Prasad A, Finch D, Stewart D, White D, van der Jagt R,
Johnston J, Belch A, Reiman T. Interim report of a phase 2 clinical trial of
lenalidomide for T-cell non-Hodgkin lymphoma. Cancer. 2010;116(19):4541–8.
30. Morschhauser F, Fitoussi O, Haioun C, Thieblemont C, Quach H, Delarue R,
Glaisner S, Gabarre J, Bosly A, Lister J, Li J, Coiffier B. A phase 2, multicentre,
single-arm, open-label study to evaluate the safety and efficacy of single-
agent lenalidomide (Revlimid) in subjects with relapsed or refractory
peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. Eur J Cancer.
2013;49(13):2869–76.
31. Toumishey E, Prasad A, Dueck G, Chua N, Finch D, Johnston J, van der Jagt
R, Stewart D, White D, Belch A, Reiman T. Final report of a phase 2 clinical
trial of lenalidomide monotherapy for patients with T-cell lymphoma.
Cancer. 2015;121(5):716–23.
32. Zinzani PL, Venturini F, Stefoni V, Fina M, Pellegrini C, Derenzini E, Gandolfi
L, Broccoli A, Argnani L, Quirini F, Pileri S, Baccarani M. Gemcitabine as
single agent in pretreated T-cell lymphoma patients: evaluation of the long-
term outcome. Ann Oncol. 2010;21(4):860–3.
33. Park BB, Kim WS, Suh C, Shin DY, Kim JA, Kim HG, Lee WS. Salvage
chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for
patients with relapsed or refractory peripheral T-cell lymphomas: a
consortium for improving survival of lymphoma (CISL) trial. Ann Hematol.
2015;94(11):1845–51.
Zhang et al. Journal of Hematology & Oncology  (2016) 9:37 Page 9 of 10
34. Zinzani PL, Musuraca G, Tani M, Stefoni V, Marchi E, Fina M, Pellegrini C,
Alinari L, Derenzini E, de Vivo A, Sabattini E, Pileri S, Baccarani M. Phase II
trial of proteasome inhibitor bortezomib in patients with relapsed or
refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25(27):4293–7.
35. Kim SJ, Yoon DH, Kang HJ, Kim JS, Park SK, Kim HJ, Lee J, Ryoo BY, Ko YH,
Huh J, Yang WI, Kim HK, Min SK, Lee SS, Do IG, Suh C, Kim WS. Bortezomib
in combination with CHOP as first-line treatment for patients with stage III/
IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial. Eur J
Cancer. 2012;48(17):3223–31.
36. Evens AM, Rosen ST, Helenowski I, Kline J, Larsen A, Colvin J, Winter JN, van
Besien KM, Gordon LI, Smith SM. A phase I/II trial of bortezomib combined
concurrently with gemcitabine for relapsed or refractory DLBCL and
peripheral T-cell lymphomas. Br J Haematol. 2013;163(1):55–61.
37. Kanagal-Shamanna R, Lehman NL, O’Donnell JP, Lim MS, Schultz DS, Chitale
DA, Bueso-Ramos CE, Medeiros LJ, Inamdar KV. Differential expression of
aurora-A kinase in T-cell lymphomas. Mod Pathol. 2013;26(5):640–7.
38. Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, Jung
J, Burack R, Zhou X, Leonard EJ, Fingert H, Danaee H, Bernstein SH. Phase II
study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and
refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol.
2014;32(1):44–50.
39. Barr PM, Li H, Spier C, Mahadevan D, LeBlanc M, Ul Haq M, Huber BD,
Flowers CR, Wagner-Johnston ND, Horwitz SM, Fisher RI, Cheson BD, Smith
SM, Kahl BS, Bartlett NL, Friedberg JW. Phase II intergroup trial of alisertib in
relapsed and refractory peripheral T-cell lymphoma and transformed
mycosis fungoides: SWOG 1108. J Clin Oncol. 2015;33(21):2399–404.
40. Gambacorti Passerini C, Farina F, Stasia A, Redaelli S, Ceccon M, Mologni L,
Messa C, Guerra L, Giudici G, Sala E, Mussolin L, Deeren D, King MH, Steurer
M, Ordemann R, Cohen AM, Grube M, Bernard L, Chiriano G, Antolini L,
Piazza R. Crizotinib in advanced, chemoresistant anaplastic lymphoma
kinase-positive lymphoma patients. J Natl Cancer Inst. 2014;106(2):
djt378.
41. Damaj G, Gressin R, Bouabdallah K, Cartron G, Choufi B, Gyan E, Banos A,
Jaccard A, Park S, Tournilhac O, Schiano-de Collela JM, Voillat L, Joly B, Le
Gouill S, Saad A, Cony-Makhoul P, Vilque JP, Sanhes L, Schmidt-Tanguy A,
Bubenheim M, Houot R, Diouf M, Marolleau JP, Bene MC, Martin A, Lamy T.
Results from a prospective, open-label, phase II trial of bendamustine in
refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol. 2013;
31(1):104–10.
42. Takahashi T, Ikejiri F, Onishi C, Kawakami K, Inoue M, Miyake T, Tanaka J,
Araki A, Maruyama R, Ohshima K, Suzumiya J. L-asparaginase-induced
complete response in a relapsed patient with Epstein-Barr virus and
cytotoxic peripheral T-cell lymphoma not otherwise specified. Intern Med.
2010;49(22):2505–8.
43. Yao G, Zhou D, Zhou M, Bao C, He D, Li L, Zhu J, He J, Shi J, Zheng W, Cai
Z, Huang H, Ye X, Xie W. Clinical analysis and prognostic significance of L-
asparaginase containing multidrug chemotherapy regimen in incipient
peripheral T-cell lymphoma. Int J Clin Exp Med. 2015;8(6):9374–83.
44. Witzig TE, Reeder C, Han JJ, LaPlant B, Stenson M, Tun HW, Macon W, Ansell
SM, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Colgan
JP, Markovic S, Nowakowski GS, Gupta M. The mTORC1 inhibitor everolimus
has antitumor activity in vitro and produces tumor responses in patients
with relapsed T-cell lymphoma. Blood. 2015;126(3):328–35.
45. Wang C, McKeithan TW, Gong Q, Zhang W, Bouska A, Rosenwald A,
Gascoyne RD, Wu X, Wang J, Muhammad Z, Jiang B, Rohr J, Cannon A,
Steidl C, Fu K, Li Y, Hung S, Weisenburger DD, Greiner TC, Smith L, Ott G,
Rogan EG, Staudt LM, Vose J, Iqbal J, Chan WC. IDH2R172 mutations define
a unique subgroup of patients with angioimmunoblastic T-cell lymphoma.
Blood. 2015;126(15):1741–52.
46. Cheminant M, Bruneau J, Kosmider O, Lefrere F, Delarue R, Gaulard P,
Radford I, Derrieux C, Hermine O, Lemonnier F. Efficacy of 5-azacytidine in a
TET2 mutated angioimmunoblastic T cell lymphoma. Br J Haematol. 2015;
168(6):913–6.
47. d’Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H,
Holte H, Osterborg A, Merup M, Brown P, Kuittinen O, Erlanson M,
Ostenstad B, Fagerli UM, Gadeberg OV, Sundstrom C, Delabie J, Ralfkiaer E,
Vornanen M, Toldbod HE. Up-front autologous stem-cell transplantation in
peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30(25):3093–9.
48. Beitinjaneh A, Saliba RM, Medeiros LJ, Turturro F, Rondon G, Korbling M,
Fayad L, Fanale MA, Alousi AM, Anderlini P, Betul O, Popat UR, Pro B, Khouri
IF. Comparison of survival in patients with T cell lymphoma after
autologous and allogeneic stem cell transplantation as a frontline strategy
or in relapsed disease. Biol Blood Marrow Transplant. 2015;21(5):855–9.
49. Witzig TE, Tang H, Micallef IN, Ansell SM, Link BK, Inwards DJ, Porrata LF,
Johnston PB, Colgan JP, Markovic SN, Nowakowski GS, Thompson CA,
Allmer C, Maurer MJ, Gupta M, Weiner G, Hohl R, Kurtin PJ, Ding H,
Loegering D, Schneider P, Peterson K, Habermann TM, Kaufmann SH. Multi-
institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib
(R115777) in patients with relapsed and refractory lymphomas. Blood. 2011;
118(18):4882–9.
50. Hosein PJ, Craig MD, Tallman MS, Boccia RV, Hamilton BL, Lewis JJ, Lossos
IS. A multicenter phase II study of darinaparsin in relapsed or refractory
Hodgkin’s and non-Hodgkin’s lymphoma. Am J Hematol. 2012;87(1):111–4.
51. Duvic M, Dummer R, Becker JC, Poulalhon N, Ortiz Romero P, Grazia
Bernengo M, Lebbe C, Assaf C, Squier M, Williams D, Marshood M, Tai F,
Prince HM. Panobinostat activity in both bexarotene-exposed and -naive
patients with refractory cutaneous T-cell lymphoma: results of a phase II
trial. Eur J Cancer. 2013;49(2):386–94.
52. Duvic M, Geskin L, Prince HM. Duration of response in cutaneous T-cell
lymphoma patients treated with denileukin diftitox: results from 3 phase III
studies. Clin Lymphoma Myeloma Leuk. 2013;13(4):377–84.
53. Assouline SE, Chang J, Cheson BD, Rifkin R, Hamburg S, Reyes R, Hui AM, Yu
J, Gupta N, Di Bacco A, Shou Y, Martin P. Phase 1 dose-escalation study of
IV ixazomib, an investigational proteasome inhibitor, in patients with
relapsed/refractory lymphoma. Blood Cancer J. 2014;4:e251.
54. Gibson JF, Foss F, Cooper D, Seropian S, Irizarry D, Barbarotta L, Lansigan F.
Pilot study of sorafenib in relapsed or refractory peripheral and cutaneous
T-cell lymphoma. Br J Haematol. 2014;167(1):141–4.
55. Dummer R, Duvic M, Scarisbrick J, Olsen EA, Rozati S, Eggmann N, Goldinger
SM, Hutchinson K, Geskin L, Illidge TM, Giuliano E, Elder J, Kim YH. Final
results of a multicenter phase II study of the purine nucleoside
phosphorylase (PNP) inhibitor forodesine in patients with advanced
cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sezary
syndrome). Ann Oncol. 2014;25(9):1807–12.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Zhang et al. Journal of Hematology & Oncology  (2016) 9:37 Page 10 of 10
